Drug Search Results
More Filters [+]

Bemiparin sodium

Alternative Names: bemiparin sodium
Latest Update: 2023-07-20
Latest Update Note: Clinical Trial Update

Product Description

Bemiparin sodium (Hibor, Ivor, Zivor, Badyket, Laboratorios Farmaceuticos Rovi SA) is a new second-generation low molecular weight heparin (LMWH). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12943485/)

Mechanisms of Action: FXa Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | Colombia | Dominican Republic | Estonia | Hong Kong | Hungary | India | Mexico | Pakistan | Philippines | Russia | Spain | Turkey | United Arab Emirates | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: ANGELA PUENTE
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bemiparin sodium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Infertility

Phase 3: COVID-19|Venous Thromboembolism|Venous Thrombosis|Pelvic Cancer|Thrombosis

Phase 2: COVID-19|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BRIF

P4

Completed

Infertility

2022-07-01

BEMICOP

P3

Unknown status

COVID-19

2021-05-31

2020-001548-24

P2

Active, not recruiting

COVID-19

2020-11-28

BEMI 2015

P3

Completed

Thrombosis

2019-02-01

Recent News Events